Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva

Summary

This is an open-label, single arm, phase 2 study designed to evaluate the efficacy of tisotumab vedotin in participants with recurrent or metastatic squamous cell carcinoma of the vulva by estimating the objective response rate. Patients will receive tisotumab vedotin every 3 weeks (21 days plus or minus 3 days). Treatment will continue until either unacceptable toxicity, progression of disease, or investigator/patient request for withdrawal.

Timeline

Start

2026-11

Primary completion

2029-03

Completion

2029-12

Drugs

Indications